Announcement • Jun 12
Poongjeon Pharmacy CO.,LTD. announced that it expects to receive KRW 3.99999812 billion in funding from Korea Investment & Securities Co., Ltd. and another investor.. Poongjeon Pharmacy CO., LTD announced a private placement to issue 796,812 common shares at an issue price of KRW 2510 per share for gross proceeds of KRW 1,999,998,120 on June 10, 2026. The transaction includes participation from new investor Cony New Technology Association No. 63. The transaction has been approved by shareholders, expected to close on June 30, 2026. The payment date of is June 30, 2026. Private placement issuance is subject to mandatory lockup for 1 year.
On the same date the company announced a private placement to issue series 3 unsecured convertible bonds for gross proceeds of KRW 2,000,000,000. The transaction will include participation from new investor, Korea Investment & Securities Co., Ltd. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on June 18, 2029. The bonds will be 100% convertible into 600,240 common shares of the company at a conversion price of KRW 3,332. The conversion period for the bonds will be between June 18, 2027 to May 18, 2029. The transaction has been approved by the board of directors of the company and is expected to close on June 18, 2026. The securities issued in the transaction will be held for a lockup period of 1 year. The payment date is June 18, 2026. New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩1.5b revenue, or US$1.0m). Market cap is less than US$100m (₩26.5b market cap, or US$17.4m). New Risk • Jun 06
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: ₩1.5b (US$989k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (₩1.5b revenue, or US$989k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₩23.6b market cap, or US$15.2m). 
